I recently had the opportunity to do two of my favourite things: visit a customer – in this case, the nuclear medicine facility at Lucas Heights, run by ANSTO (Australia's Nuclear Science and Technology Organisation) -- and play golf.
While golfing, however, I was surprised by how many of my companions weren’t aware that Australia has a nuclear reactor at all, let alone one of only five global facilities producing radioactive isotopes for MRIs and cancer treatments.
This lack of awareness, to me, encapsulates a concerning trend of Australian chemistry: world-class resources, undervalued by industry and government.
As Managing Director of Merck Life Science ANZ, I collaborate with talented scientists and researchers across all disciplines who are innovating in life sciences. Before this role I trained as a chemist, and while living in Australia I spent many years working for German companies in the chemistry industry.
I noticed that German industry and research communities take a deeply collaborative approach in fostering innovation; and I would like to see that same level of industry-research collaboration happening here in Australia.
So many of our biggest global problems – clean energy, carbon emissions, pollution – are fundamentally problems that could be solved with chemistry.
Take recycling for example. Paper can simply be mechanically recycled: it’s pulled apart and mashed back together again. Plastics, however, are a far more complex, persistent and far-reaching problem, as they degrade into microplastics that pollute every corner of the globe; even reaching the Mariana Trench, around 11 kilometres below sea level. It’s an urgent environmental issue that is gaining concern in government, research and with the public in Australia, and chemical recycling offers a real solution, especially for chemically-complex multi-plastic products.
In fact, Australia is bursting at the seams with ideas and technology. Look at Mineral Carbonisation International, which was named COP26’s Best Clean Energy Startup in 2021 for their technology to capture carbon emissions in building material. Their Chief Operating Officer, Sophia Hamblin Wang, was also recently named one of the World Economic Forum’s Young Global Leaders for 2022, joining a who’s-who of politicians, entrepreneurs and technology pioneers.
It’s also clear the renewable energy revolution hinges on chemistry advances, from batteries that push the physical capacity of lithium and graphite technology, to the ultra-high efficiency electrolyser technology from Hysata.
Hysata, a start-up spun out of the University of Wollongong in 2021, is a great example of Australian innovation commercialising breakthrough research.
This journey from research to production highlights a process I’ve seen among German industrial companies, who foster many on-going relationships with universities to support research and development.
I see these long-term partnerships as crucial to Australia’s future innovation, yet currently they are sadly under-developed.
There is no doubt that Australia is a world leader when it comes to pure research, with nearly 50 universities ranked in the top 1,000 institutions globally. We produce chemists in the mould of Sir John Cornworth, awarded the Nobel Prize in Chemistry for discovering the key to cholesterol and unlocking effective treatment for deadly heart diseases.
Translating pure research into industry innovation requires strong links between companies and universities – and for some reason, chemistry is being largely left off the table.
This contrasts with other Australian sectors, particularly in pharmacology. For example, The Translational Medical Institute in Brisbane recently welcomed start-up Infensa Bioscience to its commercial incubator, as they work to develop a treatment to limit the damage caused by heart attacks and strokes. The drug-candidate was identified in funnel-web spider venom by a University of Queensland research team.
It's this transition between research and industry that chemical sciences and the university sector must address.
COVID has created a hard reset for universities, who have been forced to diversify their funding from relying heavily on international students. Collaboration with industry offers a viable and beneficial alternative.
To unlock this capacity, I would love to see Australian universities become more flexible about the use of intellectual property. Entrepreneurship and commercialisation are not the antithesis of pure research. Instead, they are engines driving solutions to our generational problems.
A flexible and dynamic sector can also follow in the footsteps of other industries and become more diverse, bringing a broader range of experience and problem-solving skills. As a young woman in the chemistry industry, I certainly experienced my fair share of factory floors and board rooms where there were no other faces like mine. This tallies with AusBiotech’s 2022 Sector Snapshot, which found early-career gender parity declines towards leadership roles.
We need to build deep partnerships between industry and researchers, to invest in scientific discovery and tackle our complex, interconnected challenges. Australia is filled with clever, capable people – let’s bring them together to support new ideas, agile thinkers, and real innovation.
Rebecca Lee is Head of Science and Laboratory Solutions and Managing Director of Merck Life Science ANZ